PRISM BioLab Co.,LTD
206A.T · JPX
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | ¥6,137,330 | ¥12,834,688 | ¥20,116,881 | ¥20,116,881 |
| - Cash | ¥2,915,572 | ¥4,392,022 | ¥1,133,943 | ¥1,687,993 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥3,221,758 | ¥8,442,666 | ¥18,982,938 | ¥18,428,888 |
| Revenue | ¥677,330 | ¥305,620 | ¥112,926 | ¥554,396 |
| % Growth | 121.6% | 170.6% | -79.6% | – |
| Gross Profit | ¥269,757 | ¥160,540 | ¥80,306 | ¥535,136 |
| % Margin | 39.8% | 52.5% | 71.1% | 96.5% |
| EBITDA | -¥831,279 | -¥1,048,202 | -¥488,132 | ¥67,890 |
| % Margin | -122.7% | -343% | -432.3% | 12.2% |
| Net Income | -¥833,700 | -¥1,049,514 | -¥526,914 | ¥72,962 |
| % Margin | -123.1% | -343.4% | -466.6% | 13.2% |
| EPS Diluted | -22.82 | -33.53 | -19.09 | 2.06 |
| % Growth | 31.9% | -75.6% | -1,026.7% | – |
| Operating Cash Flow | -¥1,468,363 | ¥150,144 | -¥513,811 | ¥102,962 |
| Capital Expenditures | -¥64,697 | -¥211,697 | -¥34,591 | -¥5,717 |
| Free Cash Flow | -¥1,533,060 | -¥61,553 | -¥548,402 | ¥97,245 |